Moderna Inc is a biotechnology company focused on developing innovative messenger RNA (mRNA) therapeutics and vaccines for a wide array of diseases. Utilizing its proprietary mRNA technology platform, Moderna aims to harness the body's own cellular machinery to produce proteins that can help prevent or treat illnesses, including infectious diseases, cancer, and rare genetic disorders. The company gained significant attention for its development of an effective COVID-19 vaccine, but its pipeline also includes various other candidates in different stages of clinical development aimed at addressing unmet medical needs. Through its research and development efforts, Moderna seeks to transform the field of medicine and improve patient outcomes globally. Read More
U.S. stocks rise on Monday, with the Dow up 500+ points. Moderna and Cleveland-Cliffs report gains. Most S&P sectors close higher, with Fear & Greed Index at 30.3.
Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets.
But the many opportunities in front of them attract significant competition, spanning from industry behemoths with seemingly infinite resources to small, nimble players with chips on their shoulders.
The biotechnology sector is currently experiencing a significant surge in investor attention, characterized by a blend of cautious optimism and strategic focus. As of October 2025, this heightened interest is not merely an isolated phenomenon but rather a potent indicator of broader market movements, significantly impacting stock futures and the
CAMBRIDGE, MA / ACCESS Newswire / October 19, 2025 / CAMBRIDGE, MA / ACCESS Newswire / October 19, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced data regarding two of its investigational influenza candidates will be presented at IDWeek 2025, October 19-22, 2025, in Atlanta, GA. The details of the presentations are as follows:
The healthcare industry is experiencing a profound transformation, propelled by the accelerating adoption of artificial intelligence. While AI's potential has long been discussed, recent advancements in generative AI are now yielding tangible benefits, delivering measurable returns across clinical and administrative domains. This shift is further amplified by the emerging paradigm of 'agentic AI,' which promises [...]
CAMBRIDGE, MA, MA / ACCESS Newswire / October 16, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, November 6, 2025 to report its third quarter 2025 financial results, and provide a corporate update.
Let's delve into the developments on the US markets one hour before the close of the markets on Wednesday. Below, you'll find the top gainers and losers within the S&P500 index during today's session.
Let's have a look at what is happening on the US markets in the middle of the day on Wednesday. Below you can find the top S&P500 gainers and losers in today's session.
The United States government is currently in the throes of its third week of a shutdown, a fiscal impasse that commenced on October 1, 2025, following a congressional failure to enact appropriations legislation for the 2026 fiscal year. This eleventh government shutdown in U.S. history is sending ripples of
Whether you're well steeped in Foolishness or at the beginning stages of your investing journey, these are nine foundational truths not to be forgotten.
Shares of biotechnology company Moderna (NASDAQ:MRNA)
jumped in the afternoon session after the company presented promising early data for its investigational cancer antigen therapy, mRNA-4359, from a Phase I/II study.
Companies that burn cash at a rapid pace can run into serious trouble if they fail to secure funding.
Without a clear path to profitability, these businesses risk dilution, mounting debt, or even bankruptcy.
A number of stocks fell in the afternoon session after worries over worsening trade relations with China were triggered by critical comments from President Donald Trump.
